Page last updated: 2024-12-06

salicylhydroxamic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Salicylhydroxamic acid (SHAM) is a hydroxamic acid derivative of salicylic acid. It is a potent inhibitor of mitochondrial respiration and a known chelator of iron. SHAM is often used as a research tool to study the role of alternative oxidase (AOX) in plant respiration. SHAM inhibits the cytochrome c oxidase pathway, forcing cells to rely on AOX for respiration. This makes it a useful tool for investigating the role of AOX in various biological processes. SHAM has also been investigated for its potential therapeutic applications, including its ability to inhibit the growth of certain cancer cells and its antioxidant properties.'

Cross-References

ID SourceID
PubMed CID66644
CHEMBL ID309339
CHEBI ID45615
SCHEMBL ID144849
SCHEMBL ID21530845
MeSH IDM0047421

Synonyms (71)

Synonym
nsc 5088
einecs 201-934-3
nsc 193440
CHEMBL309339 ,
salicylic hydroxamic acid
2,n-dihydroxy-benzamide
chebi:45615 ,
MLS001076305
2-hydroxybenzhydroxamic acid
2-hydroxybenzohydroxamic acid
salicylohydroxamic acid
salicylohydroximic acid
nsc5088
SHA ,
benzamide,2-dihydroxy-
o-hydroxybenzohydroxamic acid
nsc-5088
nsc193440
nsc-193440
smr000059099
sham
saliaylhydroxamic acid
2-hydroxybenzenecarbohydroxamic acid
inchi=1/c7h7no3/c9-6-4-2-1-3-5(6)7(10)8-11/h1-4,9,11h,(h,8,10
n,2-dihydroxybenzamide
benzamide, n,2-dihydroxy-
salicylhydroxamic acid ,
89-73-6
salicylhydroxamic acid, 99%
DB03819
OPREA1_838400
MLS000069410 ,
NCGC00018115-01
STK387225
BMSE000772
n-hydroxysalicylamide
S0008
bdbm50015089
AKOS000120047
A843293
AKOS004905639
AKOS005260023
NCGC00018115-02
NCGC00018115-03
8q07182d0t ,
unii-8q07182d0t
HMS2234D15
FT-0602045
FS-3250
HMS3372H11
SCHEMBL144849
salicyloylhydroxamic acid
salicylhydroxamic acid [mi]
salicylhydroxamic acid [who-dd]
salicyloylhydroxamic acid [inci]
2-hydroxyphenylhydroxamic acid
n,2-dihydroxybenzamide #
n-salicylhydroxamic acid
OPERA_ID_592
DTXSID5075365
mfcd00002110
salicylhydroxamicacid
Z57842350
CS-0014188
salicyl hydroximic acid
(2-methylbiphenyl-4-yl)-methanol
Q7404461
SCHEMBL21530845
O11999
SY046520
EN300-18305

Research Excerpts

Overview

Salicylhydroxamic acid (SHAM) is a characteristic inhibitor of AOX. Several studies have explored the potentiation of strobilurin activity by SHAM. It serves as a donor to the higher oxidation state of myeloperoxidase.

ExcerptReferenceRelevance
"Salicylhydroxamic acid (SHAM) is a characteristic inhibitor of AOX, and several studies have explored the potentiation of strobilurin activity by SHAM."( A critical evaluation of the role of alternative oxidase in the performance of strobilurin and related fungicides acting at the Qo site of complex III.
Hollomon, DW; Wood, PM, 2003
)
1.04
"Salicylhydroxamic acid serves as a donor to the higher oxidation state of myeloperoxidase and thereby inhibits guaiacol oxidation."( Salicylhydroxamic acid inhibits myeloperoxidase activity.
Booth, KS; Caughey, WS; Ikeda-Saito, M; Kimura, S; Lu, L; Shelley, DA, 1991
)
2.45

Actions

ExcerptReferenceRelevance
"Salicylhydroxamic acid does not inhibit binding of 125I-labelled C3 to tonsil lymphocytes at concentrations that completely inhibit binding of 125I-labelled C3 to EAC142 cells via the nascent binding site of C3b."( Binding of fluid-phase complement components C3 and C3b to human lymphocytes.
Sim, E; Sim, RB, 1981
)
0.98

Bioavailability

ExcerptReferenceRelevance
" Although this represents a vast improvement, the low water solubility of these compounds reduces their bioavailability to the point where they are not practical substitutes for SHAM."( p-Alkyloxybenzhydroxamic acids, effective inhibitors of the trypanosome glycerol-3-phosphate oxidase.
Bienen, EJ; Clarkson, AB; Grady, RW, 1986
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
antibacterial drugA drug used to treat or prevent bacterial infections.
trypanocidal drugA drug used to treat or prevent infections caused by protozoal organisms belonging to the suborder Trypanosomatida.
EC 3.5.1.5 (urease) inhibitorEC 3.5.1.* (non-peptide linear amide C-N hydrolase) inhibitor that interferes with the activity of urease (EC 3.5.1.5), reducing hydrolysis.
EC 1.11.2.2 (myeloperoxidase) inhibitorAn EC 1.11.2.* (oxidoreductase with H2O2 as acceptor, incorporating 1 O atom into product) inhibitor that interferes with the action of myeloperoxidase (EC 1.11.2.2).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
hydroxamic acidA compound, RkE(=O)lNHOH, derived from an oxoacid RkE(=O)l(OH) (l =/= 0) by replacing -OH with -NHOH, and derivatives thereof. Specific examples of hydroxamic acids are preferably named as N-hydroxy amides.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (20)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency28.18380.044717.8581100.0000AID485294
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency10.00000.177814.390939.8107AID2147
thioredoxin glutathione reductaseSchistosoma mansoniPotency0.12590.100022.9075100.0000AID485364
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency8.91250.707912.194339.8107AID720542
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency3.98110.00137.762544.6684AID914; AID915
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency89.12510.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.99530.035520.977089.1251AID504332
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency9.92370.036619.637650.1187AID2100
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
importin subunit beta-1 isoform 1Homo sapiens (human)Potency125.89205.804836.130665.1308AID540263
snurportin-1Homo sapiens (human)Potency125.89205.804836.130665.1308AID540263
gemininHomo sapiens (human)Potency2.59290.004611.374133.4983AID624296
VprHuman immunodeficiency virus 1Potency63.09571.584919.626463.0957AID651644
survival motor neuron protein isoform dHomo sapiens (human)Potency3.98110.125912.234435.4813AID1458
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
MyeloperoxidaseHomo sapiens (human)IC50 (µMol)14.00000.02001.88117.6800AID1802478; AID701373
Thyroid peroxidaseHomo sapiens (human)IC50 (µMol)1.20000.40001.69253.3800AID1802479
Polyunsaturated fatty acid 5-lipoxygenaseRattus norvegicus (Norway rat)IC50 (µMol)30.09970.00462.018210.0000AID7184; AID7185
LactoperoxidaseBos taurus (cattle)IC50 (µMol)1.20000.40002.42506.1000AID1802479
Alternative oxidase, mitochondrialTrypanosoma brucei bruceiIC50 (µMol)5.93000.00201.48455.9300AID1387615
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
MyeloperoxidaseHomo sapiens (human)Kd2.00002.00002.00002.0000AID701371
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (21)

Processvia Protein(s)Taxonomy
hydrogen peroxide catabolic processMyeloperoxidaseHomo sapiens (human)
response to yeastMyeloperoxidaseHomo sapiens (human)
hypochlorous acid biosynthetic processMyeloperoxidaseHomo sapiens (human)
respiratory burst involved in defense responseMyeloperoxidaseHomo sapiens (human)
defense responseMyeloperoxidaseHomo sapiens (human)
response to oxidative stressMyeloperoxidaseHomo sapiens (human)
response to mechanical stimulusMyeloperoxidaseHomo sapiens (human)
removal of superoxide radicalsMyeloperoxidaseHomo sapiens (human)
response to foodMyeloperoxidaseHomo sapiens (human)
response to lipopolysaccharideMyeloperoxidaseHomo sapiens (human)
low-density lipoprotein particle remodelingMyeloperoxidaseHomo sapiens (human)
hydrogen peroxide catabolic processMyeloperoxidaseHomo sapiens (human)
negative regulation of apoptotic processMyeloperoxidaseHomo sapiens (human)
defense response to fungusMyeloperoxidaseHomo sapiens (human)
response to gold nanoparticleMyeloperoxidaseHomo sapiens (human)
defense response to bacteriumMyeloperoxidaseHomo sapiens (human)
thyroid hormone generationThyroid peroxidaseHomo sapiens (human)
response to oxidative stressThyroid peroxidaseHomo sapiens (human)
embryonic hemopoiesisThyroid peroxidaseHomo sapiens (human)
hormone biosynthetic processThyroid peroxidaseHomo sapiens (human)
hydrogen peroxide catabolic processThyroid peroxidaseHomo sapiens (human)
cellular oxidant detoxificationThyroid peroxidaseHomo sapiens (human)
response to oxidative stressLactoperoxidaseBos taurus (cattle)
thiocyanate metabolic processLactoperoxidaseBos taurus (cattle)
antibacterial humoral responseLactoperoxidaseBos taurus (cattle)
hydrogen peroxide catabolic processLactoperoxidaseBos taurus (cattle)
cellular oxidant detoxificationLactoperoxidaseBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
chromatin bindingMyeloperoxidaseHomo sapiens (human)
peroxidase activityMyeloperoxidaseHomo sapiens (human)
protein bindingMyeloperoxidaseHomo sapiens (human)
heparin bindingMyeloperoxidaseHomo sapiens (human)
heme bindingMyeloperoxidaseHomo sapiens (human)
metal ion bindingMyeloperoxidaseHomo sapiens (human)
iodide peroxidase activityThyroid peroxidaseHomo sapiens (human)
peroxidase activityThyroid peroxidaseHomo sapiens (human)
calcium ion bindingThyroid peroxidaseHomo sapiens (human)
heme bindingThyroid peroxidaseHomo sapiens (human)
peroxidase activityLactoperoxidaseBos taurus (cattle)
calcium ion bindingLactoperoxidaseBos taurus (cattle)
heme bindingLactoperoxidaseBos taurus (cattle)
thiocyanate peroxidase activityLactoperoxidaseBos taurus (cattle)
lactoperoxidase activityLactoperoxidaseBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
extracellular regionMyeloperoxidaseHomo sapiens (human)
extracellular spaceMyeloperoxidaseHomo sapiens (human)
nucleusMyeloperoxidaseHomo sapiens (human)
nucleoplasmMyeloperoxidaseHomo sapiens (human)
lysosomeMyeloperoxidaseHomo sapiens (human)
secretory granuleMyeloperoxidaseHomo sapiens (human)
azurophil granule lumenMyeloperoxidaseHomo sapiens (human)
azurophil granuleMyeloperoxidaseHomo sapiens (human)
intracellular membrane-bounded organelleMyeloperoxidaseHomo sapiens (human)
extracellular exosomeMyeloperoxidaseHomo sapiens (human)
phagocytic vesicle lumenMyeloperoxidaseHomo sapiens (human)
extracellular spaceMyeloperoxidaseHomo sapiens (human)
extracellular spaceThyroid peroxidaseHomo sapiens (human)
plasma membraneThyroid peroxidaseHomo sapiens (human)
cell surfaceThyroid peroxidaseHomo sapiens (human)
extracellular spaceThyroid peroxidaseHomo sapiens (human)
extracellular spaceLactoperoxidaseBos taurus (cattle)
cytoplasmLactoperoxidaseBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (66)

Assay IDTitleYearJournalArticle
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1802479LPO/TPO Selectivity Assay from Article 10.1074/jbc.M113.507756: \\Potent reversible inhibition of myeloperoxidase by aromatic hydroxamates.\\2013The Journal of biological chemistry, Dec-20, Volume: 288, Issue:51
Potent reversible inhibition of myeloperoxidase by aromatic hydroxamates.
AID1802478Myeloperoxidase Assay from Article 10.1074/jbc.M113.507756: \\Potent reversible inhibition of myeloperoxidase by aromatic hydroxamates.\\2013The Journal of biological chemistry, Dec-20, Volume: 288, Issue:51
Potent reversible inhibition of myeloperoxidase by aromatic hydroxamates.
AID1431829Anti-parasitic activity against diminazene, pentamidine and melaminophenyl arsenical-resistant bloodstream trypomastigote stage of Trypanosoma brucei brucei B48 harboring TbAT1 deletion mutant after 48 hrs by alamar blue based fluorescence assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Conjugates of 2,4-Dihydroxybenzoate and Salicylhydroxamate and Lipocations Display Potent Antiparasite Effects by Efficiently Targeting the Trypanosoma brucei and Trypanosoma congolense Mitochondrion.
AID1394622Anti-parasitic activity against bloodstream trypomastigote stage of wild-type Trypanosoma brucei brucei Lister 427 after 48 hrs in presence of 5 mM glycerol by resazurin-based assay2018European journal of medicinal chemistry, Apr-25, Volume: 150Inhibition of trypanosome alternative oxidase without its N-terminal mitochondrial targeting signal (ΔMTS-TAO) by cationic and non-cationic 4-hydroxybenzoate and 4-alkoxybenzaldehyde derivatives active against T. brucei and T. congolense.
AID7185Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1)1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships.
AID1059430Inhibition of recombinant human IDO1 expressed in Escherichia coli EC538 using L-tryptophan as substrate at 1 mM after 1 hr relative to control2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Discovery and characterisation of hydrazines as inhibitors of the immune suppressive enzyme, indoleamine 2,3-dioxygenase 1 (IDO1).
AID701373Inhibition of recombinant human myeloperoxidase2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Evaluation of new scaffolds of myeloperoxidase inhibitors by rational design combined with high-throughput virtual screening.
AID1431843Trypanocidal activity against bloodstream trypomastigote stage of wild-type Trypanosoma brucei brucei Lister 427 assessed as inhibition of respiration in presence of glycerol2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Conjugates of 2,4-Dihydroxybenzoate and Salicylhydroxamate and Lipocations Display Potent Antiparasite Effects by Efficiently Targeting the Trypanosoma brucei and Trypanosoma congolense Mitochondrion.
AID382113Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 after 48 hrs by LDH reporter assay2008Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9
Structural insights into the Plasmodium falciparum histone deacetylase 1 (PfHDAC-1): A novel target for the development of antimalarial therapy.
AID158873In vitro antimalarial activity against Plasmodium falciparum1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
Mechanism-based development of new antimalarials: synthesis of derivatives of artemisinin attached to iron chelators.
AID1394624Resistance factor, ratio of EC50 for bloodstream trypomastigote stage of wild-type Trypanosoma brucei brucei Lister 427 in presence of 5 mM glycerol to EC50 for bloodstream trypomastigote stage of wild-type Trypanosoma brucei brucei Lister 4272018European journal of medicinal chemistry, Apr-25, Volume: 150Inhibition of trypanosome alternative oxidase without its N-terminal mitochondrial targeting signal (ΔMTS-TAO) by cationic and non-cationic 4-hydroxybenzoate and 4-alkoxybenzaldehyde derivatives active against T. brucei and T. congolense.
AID1264486Reversible inhibition of human recombinant myeloperoxidase at 100 uM for 1 hr followed by washout by ELISA in presence of 50 uM H2O22015ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10
Thioxo-dihydroquinazolin-one Compounds as Novel Inhibitors of Myeloperoxidase.
AID388275Inhibition of rat recombinant peptidylglycine alpha-amidating monooxygenase assessed as inhibition of N-dansyl-Tyr-Val-Gly amidation2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Substituted hippurates and hippurate analogs as substrates and inhibitors of peptidylglycine alpha-hydroxylating monooxygenase (PHM).
AID1394630Resistance factor, ratio of EC50 for bloodstream trypomastigote stage of Trypanosoma brucei brucei with AQP2/3-dd knock out to EC50 for bloodstream trypomastigote stage of wild-type Trypanosoma brucei brucei Lister 4272018European journal of medicinal chemistry, Apr-25, Volume: 150Inhibition of trypanosome alternative oxidase without its N-terminal mitochondrial targeting signal (ΔMTS-TAO) by cationic and non-cationic 4-hydroxybenzoate and 4-alkoxybenzaldehyde derivatives active against T. brucei and T. congolense.
AID1431832Cytotoxicity against HFF cells after 30 hrs by resazurin based fluorimetric assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Conjugates of 2,4-Dihydroxybenzoate and Salicylhydroxamate and Lipocations Display Potent Antiparasite Effects by Efficiently Targeting the Trypanosoma brucei and Trypanosoma congolense Mitochondrion.
AID388280Inhibition of Blattella germanica peptidylamidoglycolate lyase assessed as ascorbate-independent dealkylation of alpha-hydroxy-hipurate2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Substituted hippurates and hippurate analogs as substrates and inhibitors of peptidylglycine alpha-hydroxylating monooxygenase (PHM).
AID1431831Cytostatic activity against HEK293T cells after 30 hrs by resazurin based fluorimetric assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Conjugates of 2,4-Dihydroxybenzoate and Salicylhydroxamate and Lipocations Display Potent Antiparasite Effects by Efficiently Targeting the Trypanosoma brucei and Trypanosoma congolense Mitochondrion.
AID1394618Inhibition of recombinant N-terminal His6 tagged SUMO-fused Trypanosoma brucei brucei TC221 TAO MTS deletion mutant expressed in Escherichia coli FN102 preincubated for 2 mins followed by ubiquinol-1 addition measured over 2 mins by double beam-dual wavel2018European journal of medicinal chemistry, Apr-25, Volume: 150Inhibition of trypanosome alternative oxidase without its N-terminal mitochondrial targeting signal (ΔMTS-TAO) by cationic and non-cationic 4-hydroxybenzoate and 4-alkoxybenzaldehyde derivatives active against T. brucei and T. congolense.
AID1431827Reduction in oxygen consumption in bloodstream trypomastigote stage of wild-type Trypanosoma brucei brucei Lister 427 at 50 uM measured immediately for 120 mins by fluorescent oxygen reporter probe based fluorimetric assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Conjugates of 2,4-Dihydroxybenzoate and Salicylhydroxamate and Lipocations Display Potent Antiparasite Effects by Efficiently Targeting the Trypanosoma brucei and Trypanosoma congolense Mitochondrion.
AID1394627Anti-parasitic activity against bloodstream trypomastigote stage of Trypanosoma brucei brucei with AQP2/3-dd knock out after 48 hrs by resazurin-based assay2018European journal of medicinal chemistry, Apr-25, Volume: 150Inhibition of trypanosome alternative oxidase without its N-terminal mitochondrial targeting signal (ΔMTS-TAO) by cationic and non-cationic 4-hydroxybenzoate and 4-alkoxybenzaldehyde derivatives active against T. brucei and T. congolense.
AID521050Inhibition of respiration in Trypanosoma brucei brucei 427 bloodstream form mitochondria using glycerol-3-phosphate as substrate at 10 uM2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
The mitochondrion is a site of trypanocidal action of the aromatic diamidine DB75 in bloodstream forms of Trypanosoma brucei.
AID1431847Anti-parasitic activity against bloodstream trypomastigote stage of Trypanosoma brucei brucei Lister 427 over-expressing TAO relative to bloodstream trypomastigote stage of wild-type Trypanosoma brucei brucei Lister 4272017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Conjugates of 2,4-Dihydroxybenzoate and Salicylhydroxamate and Lipocations Display Potent Antiparasite Effects by Efficiently Targeting the Trypanosoma brucei and Trypanosoma congolense Mitochondrion.
AID1431844Resistant factor, ratio of EC50 for bloodstream trypomastigote stage of wild-type Trypanosoma brucei brucei Lister 427 assessed as inhibition of respiration in presence of glycerol to EC50 for bloodstream trypomastigote stage of wild-type Trypanosoma bruc2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Conjugates of 2,4-Dihydroxybenzoate and Salicylhydroxamate and Lipocations Display Potent Antiparasite Effects by Efficiently Targeting the Trypanosoma brucei and Trypanosoma congolense Mitochondrion.
AID1431828Anti-parasitic activity against bloodstream trypomastigote stage of wild-type Trypanosoma brucei brucei Lister 427 after 48 hrs by alamar blue based fluorescence assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Conjugates of 2,4-Dihydroxybenzoate and Salicylhydroxamate and Lipocations Display Potent Antiparasite Effects by Efficiently Targeting the Trypanosoma brucei and Trypanosoma congolense Mitochondrion.
AID1124478Antitumor activity against mouse L1210 cells allografted in C6D2F1 mouse at 10 to 1000 mg/kg, ip for 8 days starting from day 1 of challenge relative to control1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Synthesis of hydroxy- and amino-substituted benzohydroxamic acids: inhibition of ribonucleotide reductase and antitumor activity.
AID701371Binding affinity to recombinant human myeloperoxidase2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Evaluation of new scaffolds of myeloperoxidase inhibitors by rational design combined with high-throughput virtual screening.
AID1387615Inhibition of recombinant Trypanosoma brucei brucei alternative oxidase using ubiquinol-1 as substrate incubated for 2 mins followed by substrate addition by spectrophotometric method2018ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9
SAR of 4-Alkoxybenzoic Acid Inhibitors of the Trypanosome Alternative Oxidase.
AID1431830Anti-parasitic activity against bloodstream form of Trypanosoma congolense IL3000 after 48 hrs by alamar blue based fluorescence assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Conjugates of 2,4-Dihydroxybenzoate and Salicylhydroxamate and Lipocations Display Potent Antiparasite Effects by Efficiently Targeting the Trypanosoma brucei and Trypanosoma congolense Mitochondrion.
AID521048Inhibition of respiration in Trypanosoma brucei brucei 427 bloodstream form mitochondria using glycerol-3-phosphate as substrate at 2 mM2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
The mitochondrion is a site of trypanocidal action of the aromatic diamidine DB75 in bloodstream forms of Trypanosoma brucei.
AID1394631Resistance factor, ratio of EC50 for bloodstream trypomastigote stage of Trypanosoma brucei brucei AQP triple knock out to EC50 for bloodstream trypomastigote stage of wild-type Trypanosoma brucei brucei Lister 4272018European journal of medicinal chemistry, Apr-25, Volume: 150Inhibition of trypanosome alternative oxidase without its N-terminal mitochondrial targeting signal (ΔMTS-TAO) by cationic and non-cationic 4-hydroxybenzoate and 4-alkoxybenzaldehyde derivatives active against T. brucei and T. congolense.
AID1104264Inhibition of respiratory activity in Botryotinia fuckeliana mycelium assessed as decrease in rate of oxygen consumption at 2 mM by Clark-type oxygen electrode recording analysis in presence of glucose (Rvb = 0%)2009Pest management science, Dec, Volume: 65, Issue:12
Inhibitory effect of bionic fungicide 2-allylphenol on Botrytis cinerea (Pers. ex Fr.) in vitro.
AID1431823Reduction in oxygen consumption in bloodstream trypomastigote stage of wild-type Trypanosoma brucei brucei Lister 427 measured immediately for 120 mins by fluorescent oxygen reporter probe based fluorimetric assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Conjugates of 2,4-Dihydroxybenzoate and Salicylhydroxamate and Lipocations Display Potent Antiparasite Effects by Efficiently Targeting the Trypanosoma brucei and Trypanosoma congolense Mitochondrion.
AID1394629Anti-parasitic activity against bloodstream trypomastigote stage of pentamidine/diminazene/melaminophenyl arsenical resistant Trypanosoma brucei B48 after 48 hrs by resazurin-based assay2018European journal of medicinal chemistry, Apr-25, Volume: 150Inhibition of trypanosome alternative oxidase without its N-terminal mitochondrial targeting signal (ΔMTS-TAO) by cationic and non-cationic 4-hydroxybenzoate and 4-alkoxybenzaldehyde derivatives active against T. brucei and T. congolense.
AID382112Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 after 48 hrs by LDH reporter assay2008Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9
Structural insights into the Plasmodium falciparum histone deacetylase 1 (PfHDAC-1): A novel target for the development of antimalarial therapy.
AID1124479Antitumor activity against ip dosed mouse L1210 cells allografted in C6D2F1 mouse assessed as dose to achieve maximum life span administered for 8 days starting from day 1 of challenge1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Synthesis of hydroxy- and amino-substituted benzohydroxamic acids: inhibition of ribonucleotide reductase and antitumor activity.
AID1394628Anti-parasitic activity against bloodstream trypomastigote stage of Trypanosoma brucei brucei with AQP triple knock out after 48 hrs by resazurin-based assay2018European journal of medicinal chemistry, Apr-25, Volume: 150Inhibition of trypanosome alternative oxidase without its N-terminal mitochondrial targeting signal (ΔMTS-TAO) by cationic and non-cationic 4-hydroxybenzoate and 4-alkoxybenzaldehyde derivatives active against T. brucei and T. congolense.
AID1387616Antiparasitic activity against bloodstream trypomastigote stage of wild type Trypanosoma brucei brucei Lister 427 after 48 hrs by resazurin dye based fluorescence assay2018ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9
SAR of 4-Alkoxybenzoic Acid Inhibitors of the Trypanosome Alternative Oxidase.
AID1431846Inhibition of recombinant MTS-deficient N-terminal His6-tagged and SUMO-tagged Trypanosoma alternative oxidase expressed in Escherichia coli FN102 using ubiquinol-1 as substrate2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Conjugates of 2,4-Dihydroxybenzoate and Salicylhydroxamate and Lipocations Display Potent Antiparasite Effects by Efficiently Targeting the Trypanosoma brucei and Trypanosoma congolense Mitochondrion.
AID1104263Inhibition of respiratory activity in Botryotinia fuckeliana mycelium assessed as decrease in rate of oxygen consumption at 2 mM by Clark-type oxygen electrode recording analysis in presence of succinate (Rvb = 0%)2009Pest management science, Dec, Volume: 65, Issue:12
Inhibitory effect of bionic fungicide 2-allylphenol on Botrytis cinerea (Pers. ex Fr.) in vitro.
AID293164Inhibition of metallo-beta-lactamases FEZ12007Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4
Inhibitors of the FEZ-1 metallo-beta-lactamase.
AID1124476Inhibition of ribonucleotide reductase purified from rat Novikoff hepatoma assessed as inhibition of [3H]CDP to [3H]dCDP conversion after 40 mins1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Synthesis of hydroxy- and amino-substituted benzohydroxamic acids: inhibition of ribonucleotide reductase and antitumor activity.
AID7184In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1)1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships.
AID1394621Anti-parasitic activity against bloodstream trypomastigote stage of wild-type Trypanosoma brucei brucei Lister 427 after 48 hrs by resazurin-based assay2018European journal of medicinal chemistry, Apr-25, Volume: 150Inhibition of trypanosome alternative oxidase without its N-terminal mitochondrial targeting signal (ΔMTS-TAO) by cationic and non-cationic 4-hydroxybenzoate and 4-alkoxybenzaldehyde derivatives active against T. brucei and T. congolense.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (238)

TimeframeStudies, This Drug (%)All Drugs %
pre-199075 (31.51)18.7374
1990's38 (15.97)18.2507
2000's76 (31.93)29.6817
2010's42 (17.65)24.3611
2020's7 (2.94)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.93

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.93 (24.57)
Research Supply Index5.53 (2.92)
Research Growth Index4.46 (4.65)
Search Engine Demand Index48.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.93)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (1.19%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other249 (98.81%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]